BSX Launches Neurovascular Stent – Analyst Blog

Recently, Boston Scientific Corporation (BSX) launched its fourth generation Neuroform EZ Stent System in the US and Europe, used for the advanced treatment of wide-necked aneurysms. The Neuroform EZ adjunctive Stent System offers flexibility with advanced treatment options for complex brain anatomy.

The launch of the Neuroform EZ adjunctive Stent System expands the product portfolio of Boston Scientific’s Neurovascular division, which includes a line of catheters used in thrombolysis and is the only company that provides stent delivery technology through over the wire and open catheter systems.

In the second quarter 2010, the worldwide Neurovascular revenue declined 5% year over year to $82 million, while maintaining its global leadership. The decline was due to delay in the product launches and pricing pressures. However, with new product launches the company expects this division to see growth in the second half of fiscal 2010.

Boston Scientific expects to expand the Neuroform EZ offering to other regions over the coming months.

Boston Scientific manufactures medical devices and products for use in a broad range of interventional medical specialties. Its Interventional Cardiology (“ICD”) products include various types of stents, such as total Coronary Stent Systems including- drug-eluting and bare-metal stents, with worldwide Drug Eluting Stents (“DES”) market share remaining consistent at 38%. The company faces significant competition across its product portfolio from competitors such as Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).
 
Presently, we have a ‘Neutral’ recommendation on Boston Scientific.